News | Cardiovascular Clinical Studies | June 21, 2022

Renibus Therapeutics Announces Positive Interim Data from RBT-1 Phase 2 Trial

RBT-1 met primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning; positive data supports the potential for RBT-1 to impact clinical outcomes in cardiothoracic surgery patients 

Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced that its lead clinical candidate, RBT-1, met the primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning in a pre-specified interim Phase 2 data analysis

June 21, 2022 — Renibus Therapeutics (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today announced that its lead clinical candidate, RBT-1, met the primary endpoint of increasing the expression of biomarkers of cytoprotective preconditioning in a pre-specified interim Phase 2 data analysis. While the trial was not powered to demonstrate statistical significance beyond its primary endpoint, RBT-1 did achieve statistical significance in multiple, pre-specified clinically relevant endpoints, including a reduction in ICU days, ventilator days, and 30-day re-admission rates. The positive data supports RBT-1’s potential to impact clinical outcomes following cardiothoracic surgery. The Phase 2 randomized, multi-center placebo-controlled trial evaluated the effect of RBT-1 in patients undergoing coronary artery bypass graft (CABG) and/or cardiac valve surgery. The interim data was obtained from 60 patients who were randomized to receive active drug (2 dose groups) or placebo. 

Summary of Interim Data 

The pre-specified interim analysis of Phase 2 RBT-1 data when compared to placebo supported: 

  • A statistically significant (p value <0.0001) increase in biomarkers of cytoprotective preconditioning, which achieved the trial’s primary endpoint; 
  • A statistically significant (p value <0.05) reduction in days in the ICU and days on ventilator among patients receiving active treatment; 
  • A clinically meaningful reduction in rates of AKI (-52%) and MAKE30 (-78%); 
  • An overall reduction in length of hospital stay by 2 days; 
  • A statistically significant (p value <0.003) reduction in 30-day hospital readmission rates; 
  • A generally well-tolerated safety profile. 

“The administration of RBT-1 to patients undergoing cardiothoracic surgery has the potential to improve patient outcomes and address a critical unmet patient need,” said Dr. Bhupinder Singh, Chief Medical Officer of Renibus and Clinical Professor at the University of California, Irvine School of Medicine. “The interim analysis suggested positive patient benefits in clinically relevant outcomes after administration of RBT-1 when compared to placebo.” 

“We are highly encouraged that RBT-1 met the primary endpoint and demonstrated its potential to reduce the risk of postoperative complications following cardiothoracic surgery in the interim data analysis from the Phase 2 trial,” said Renibus’ Chairman and CEO, Frank Stonebanks. “We look forward to continuing the development of RBT-1 and preparing for its next set of milestones.” 

Based on this positive interim analysis, Renibus requested and was granted an End of Phase 2 meeting to discuss the Company’s plans for the initiation of a pivotal Phase 3 clinical trial later this year. 

Phase 2 Clinical Trial Design 

The primary objective of the Phase 2 randomized, multi-center, placebo-controlled trial was to evaluate the effect of RBT-1 (stannous protoporphyrin and iron sucrose) on biomarkers of cytoprotective preconditioning as well as clinical outcomes in patients undergoing CABG and/or cardiac valve surgery. The trial includes multiple sites in Australia, Canada and the United States.  

For more information: www.renibus.com

Related Content

Feature | Cardiovascular Surgery

The global vascular graft market size was valued at $4,993.64 million in 2020, and is projected to reach $8,138.68 ...

Home June 14, 2022
Home
News | Cardiovascular Surgery

June 14, 2022 — The Society for Vascular Surgery Vascular Quality Initiative (SVS VQI), a nonprofit organization ...

Home June 14, 2022
Home
News | Cardiovascular Surgery

April 29, 2022 – Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking ...

Home April 29, 2022
Home
News | Cardiovascular Surgery
January 18, 2022 – Evonik Venture Capital has invested in CircumFix Solutions, a Tennessee-based start-up that has ...
Home February 18, 2022
Home
News | Cardiovascular Surgery
February 15, 2022 – A multicenter, retrospective database analysis suggests improved open abdominal aortic aneurysm (AAA ...
Home February 15, 2022
Home
News | Cardiovascular Surgery

February 11, 2022 — Riverside Community Hospital has earned a distinguished three-star rating from The Society of ...

Home February 11, 2022
Home
News | Cardiovascular Surgery

November 23, 2021 — A novel device called venous external support (VEST) may lead to increased longevity and durability ...

Home November 23, 2021
Home
News | Cardiovascular Surgery

November 22, 2021 — The Minneapolis Heart Institute Foundation (MHIF) announced the publication of research showing ...

Home November 22, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — Moderna Inc. announced positive data from the AstraZeneca-led Phase 2 (EPICCURE) study evaluating ...

Home November 18, 2021
Home
News | Cardiovascular Surgery

November 18, 2021 — People who are on the antiplatelet medication ticagrelor and need coronary artery bypass surgery may ...

Home November 18, 2021
Home
Subscribe Now